1. Home
  2. MFM vs CRBP Comparison

MFM vs CRBP Comparison

Compare MFM & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Municipal Income Trust

MFM

MFS Municipal Income Trust

HOLD

Current Price

$5.34

Market Cap

224.5M

Sector

Finance

ML Signal

HOLD

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$10.39

Market Cap

190.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MFM
CRBP
Founded
1986
2009
Country
United States
United States
Employees
N/A
36
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
224.5M
190.3M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
MFM
CRBP
Price
$5.34
$10.39
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$45.50
AVG Volume (30 Days)
287.2K
343.4K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
4.08%
N/A
EPS Growth
N/A
N/A
EPS
0.03
N/A
Revenue
N/A
$4,822,272.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$116.00
P/E Ratio
$178.67
N/A
Revenue Growth
N/A
97.62
52 Week Low
$5.07
$7.12
52 Week High
$5.67
$20.56

Technical Indicators

Market Signals
Indicator
MFM
CRBP
Relative Strength Index (RSI) 39.31 59.38
Support Level $5.23 $8.30
Resistance Level $5.47 $10.74
Average True Range (ATR) 0.06 0.54
MACD -0.00 0.03
Stochastic Oscillator 0.00 68.27

Price Performance

Historical Comparison
MFM
CRBP

About MFM MFS Municipal Income Trust

MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but it may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Share on Social Networks: